We are live on ! Find out more
XTLB

XTL Biopharmaceuticals
XTLB

4 hedge funds and large institutions have $232K invested in XTL Biopharmaceuticals in 2020 Q4 according to their latest regulatory filings, with 1 funds opening new positions, 1 increasing their positions, reducing their positions, and 1 closing their positions.

New
Increased
Maintained
Reduced
Closed

0% more funds holding

Funds holding: 4 → 4 (0)

0% more ownership

Funds ownership: 0.02% → 0.02% (+0%)

0% more first-time investments, than exits

New positions opened: 1 | Existing positions closed: 1

73% less capital invested

Capital invested by funds: $848K → $232K (-$616K)

Holders
4
Holders Change
–
Holders Change %
0%
% of All Funds
0.07%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
1
Increased
1
Reduced
–
Closed
1
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
Renaissance Technologies
Renaissance Technologies
New York
+$46.3K
2
Morgan Stanley
Morgan Stanley
New York
+$22.3K

Top Sellers

Rank Fund Capital Flow
1
UBS Group
UBS Group
Switzerland
-$2K
Name Holding Trade Value Shares
Change 		Change in
Stake
Morgan Stanley
1
Morgan Stanley
New York
$172K +$22.3K +2,348 +20%
Renaissance Technologies
2
Renaissance Technologies
New York
$59K +$46.3K +4,883 New
NC
3
Noked Capital
Israel
$603 – – –
NI
4
Noked Israel
Israel
$603 – – –
UBS Group
5
UBS Group
Switzerland
– -$2K -259 Closed

XTLB Hedge Fund Activity: Q4 2020 in Review

4 of the 5,652 institutional investors tracked by Wall St. Rank reported a position in XTL Biopharmaceuticals (XTLB) for Q4 2020, worth a combined $232K — down 73% from $848K a quarter earlier.

Fund positioning in XTLB was balanced in Q4 2020: 1 fund opened new positions, 1 closed out, 1 added to existing stakes and 0 trimmed.

The largest buyer was Renaissance Technologies, opening a new position worth an estimated $46.3K. The largest seller was UBS Group, exiting entirely with an estimated $2K sold.

  • 4 institutional investors held XTL Biopharmaceuticals (XTLB) as of Q4 2020, unchanged from Q3 2020.
  • Funds reported $232K of XTL Biopharmaceuticals stock for Q4 2020, down 73% quarter-over-quarter.
  • 1 fund opened new XTL Biopharmaceuticals positions in Q4 2020 and 1 closed out, a net change of 0 holders.
  • The largest XTL Biopharmaceuticals buyer in Q4 2020 was Renaissance Technologies, an estimated $46.3K added.
  • The largest XTL Biopharmaceuticals seller in Q4 2020 was UBS Group, an estimated $2K sold.

Based on aggregated 13F filings for Q4 2020.